Functional inactivation of tumor susceptibility gene tsg101 leads to cellular transformation and tumorigenesis in mice. While human TSG101 is located in a region where frequent loss of heterozygosity can be detected in a variety of cancers, no genomic deletion in TSG101 gene has been reported, casting a doubt on the role of TSG101 as a classical tumor suppressor. Some studies have revealed that TSG101 is a frequent target of splicing defects, which correlate with cellular stress and p53 status. Furthermore, recent reports have identified TSG101 as a part of the MDM2/p53 regulatory circuitry, a well-recognized circuitry that upon deregulation results in tumorigenesis. Interestingly, overexpression of tsg101 from an adventitious promoter also leads to neoplastic transformation. On the basis of this information, we have analysed TSG101 gene expression in 20 human papillary thyroid carcinomas (PTCs) by immunohistochemistry and demonstrated that the overexpression of TSG101 protein is closely associated with human PTCs. Further sequence analysis reveals no mutation in cDNA region encoding steadiness box in these PTC specimens, indicating that the upregulation of TSG101 protein is not caused by the alteration of this region. In situ hybridization analysis confirms that overexpression of TSG101 also occurs at the transcriptional level. In addition, semi-quantitative RT -PCR and subsequent Southern hybridization verify that the amounts of TSG101 transcripts are indeed lower in three normal thyroid tissues than in PTC specimens. Here we report the upregulation of TSG101 expression in PTC cells, providing the first evidence of the association of TSG101 overexpression with human tumors and suggesting that upregulation of TSG101 steady-state level might play a role in mediating tumorigenesis of human PTC.
Functional inactivation of tumor susceptibility gene tsg101 leads to cellular transformation and tumorigenesis in mice. While human TSG101 is located in a region where frequent loss of heterozygosity can be detected in a variety of cancers, no genomic deletion in TSG101 gene has been reported, casting a doubt on the role of TSG101 as a classical tumor suppressor. Some studies have revealed that TSG101 is a frequent target of splicing defects, which correlate with cellular stress and p53 status. Furthermore, recent reports have identified TSG101 as a part of the MDM2/p53 regulatory circuitry, a well-recognized circuitry that upon deregulation results in tumorigenesis. Interestingly, overexpression of tsg101 from an adventitious promoter also leads to neoplastic transformation. On the basis of this information, we have analysed TSG101 gene expression in 20 human papillary thyroid carcinomas (PTCs) by immunohistochemistry and demonstrated that the overexpression of TSG101 protein is closely associated with human PTCs. Further sequence analysis reveals no mutation in cDNA region encoding steadiness box in these PTC specimens, indicating that the upregulation of TSG101 protein is not caused by the alteration of this region. In situ hybridization analysis confirms that overexpression of TSG101 also occurs at the transcriptional level. In addition, semi-quantitative RT -PCR and subsequent Southern hybridization verify that the amounts of TSG101 transcripts are indeed lower in three normal thyroid tissues than in PTC specimens. Here we report the upregulation of TSG101 expression in PTC cells, providing the first evidence of the association of TSG101 overexpression with human tumors and suggesting that upregulation of TSG101 steady-state level might play a role in mediating tumorigenesis of human PTC.
Introduction
It has been shown that functional inactivation of tsg101 in mouse NIH3T3 fibroblasts leads to cellular transformation, and the transformed cells can form metastatic tumors in nude mice. The neoplastic transformation and tumourigenesis are reversible by restoration of tsg101 function (Li and Cohen, 1996) . The human homologue TSG101 has been isolated and mapped to chromosome 11p, bands 15.1-15.2 (Li et al., 1997) , a region known to exhibit a high incidence of loss of heterozygosity in a variety of human malignancies (Ali et al., 1987; Baffa et al., 1996; Byrne et al., 1993; Lothe et al., 1993; Ludwig et al., 1991; Reeve et al., 1989; Shaw and Knowles, 1995; Weitzel et al., 1994) , suggesting that TSG101 might be a tumor suppressor. Although no genomic deletion has been identified, aberrant transcripts can be found in various tumors and their matched normal tissues (Carney et al., 1998; Chang et al., 1999; Lee and Feinberg, 1997; Lin et al., 1998a,b; Wang et al., 2000; Willeke et al., 1998) , including thyroid tumors (McIver et al., 2000) . Abnormally spliced transcripts of TSG101 have been found to very closely correlate with tumor grade and p53 mutation in breast cancer samples. Stress conditions, such as hypoxia, also induce splicing transcripts in primary lymphocytes (Turpin et al., 1999) . In addition, induction of p53 by g-irradiation prevents the accumulation of aberrant TSG101 transcripts in cancer cells. Hence, while abnormal TSG101 RNA splicing is probably unrelated to oncogenic process, it does reflect the cellular environment during cancer development (Moyret-Lalle et al., 2001) .
TSG101 gene is expressed ubiquitously in human organs (Li et al., 1997) . Localization of TSG101 has been found to be cell cycle-dependent in synchronized cell lines, occurring in the nucleus and Golgi complex during interphase, dispersed more generally throughout the cytoplasm when cells reach late S phase, and in mitotic spindles and centrosomes during mitosis (Xie et al., 1998; Zhong et al., 1998) . Evidence suggests that normal TSG101 expression may be stringently controlled within a narrow range (Feng et al., 2000) since either deficiency or overexpression of the tsg101 can cause neoplastic formation (Li and Cohen, 1996) . How the perturbation of tsg101 expression leads to neoplasm is currently unclear. One recent report on tsg101 knockout mice indicates that tsg101 deficiency results in p53 accumulation, growth arrest and early embryonic lethality . Interestingly, TSG101 has been demonstrated to participate in a feedback control loop with MDM2 as a central part where upregulation of TSG101 inhibits ubiquitination and degradation of MDM2, thereby decreasing cellular p53 level, whereas elevation of p53 upregulates MDM2 and subsequently accelerates the decay of TSG101 . The equilibration between TSG101-dependent stabilization of MDM2 and MDM2-mediated proteolysis of both TSG101 and p53 determines the effect of TSG101 on MDM2/p53 feedback control loop, a well-known control loop that upon deregulation results in tumorigenesis. In this study, we screen 20 human papillary thyroid carcinomas (PTCs) by immunohistochemical staining and in situ hybridization analysis on paraffin-embedded tissues to explore the role of TSG101 in thyroid tumorigenesis.
Results

Demonstration of the specificity of anti-TSG101 antiserum
The GST-TSG(1 -291) and GST-TSG(214 -390) fusion proteins were expressed individually in E. coli strain DH5a and then purified by affinity chromatography on glutathione-conjugated agarose beads. Rabbit polyclonal antisera, #654 and #820 (Figure 1a ), were produced using these fusion proteins as immunogens. The specificity of these antisera was verified by Western blot analysis, confirming that these antibodies could recognize the endogenous TSG101 protein expressed in SK-Hep-1, a human hepatocellular carcinoma cell line. As shown in Figure 1b , antiserum #654 detected a prominent band in the same position as the band that could be detected by a commercial TSG101 antibody (sc-6037, Santa Cruz Biotechnology, Santa Cruz, CA, USA) (Figure 1b; lanes 1 and 3) . The specificity of antiserum #654 was confirmed as no band in the same position could be detected by preimmune serum and GST-TSG(1 -291) fusion protein-absorbed antiserum ( Figure 1b ; lanes 2 and 5), while the particular protein band at the same position could still be detected by GST protein-absorbed antiserum #654 (Figure 1b, lane  4) . Also, the specificity of antiserum #654 was further demonstrated by the fact that the immune serum, not the preimmune serum, detected endogenous TSG101 protein in SK-Hep-1 cells by immunocytochemical staining (data not shown). Similar results were obtained with antiserum #820 (data not shown).
Detection of increased TSG101 expression in PTC specimens by immunohistochemistry
Immunohistochemical analyses of 20 PTC specimens were then performed using antiserum #654. Two representative PTC specimens with different histologic features are shown in Figures 2 and 3. Intense cytoplasmic staining was seen in all the neoplastic epithelial cells of each PTC specimen (Figures 2 and 3 ; Table 1 ). The non-neoplastic follicular cells adjacent to carcinoma tissue revealed either negative staining or only cytoplasmic dot-staining which localized asymmetrically by the side of nucleus, and occasionally staining in the nucleus (Figures 2c and 3d ). The cytoplasmic dot-staining pattern was quite distinct in contrast to the diffuse staining patterns seen in neoplastic cells. The non-specific background staining was greatly reduced, whereas the intensity of the immunoreactivity did not undergo a significant change while replacing the antiserum #654 with GST-absorbed antiserum (Figures 2b and 3b ). However, immunoreactivity did disappear when preimmune serum was used instead of antiserum #654 (Figures 2d and 3c ). To further confirm the specificity of antiserum #654, rabbit antiserum #820 against carboxyl terminus (amino acid residues 214 -390) of TSG101 protein was used to immunostain the same specimens. Both antisera essentially gave similar staining patterns (data not shown).
Overexpression of TSG101 protein is not caused by the mutation of steadiness box
The mutation at C-terminal steadiness box of TSG101 protein has been shown to cause the accumulation of this protein at several times the wild-type protein level (Feng et al., 2000) . To detect the presence of mutation, the cDNA encompassing this region was amplified and sequenced. As summarized in Table 1 , no mutation in steadiness box could be detected in the PTCs analysed.
Upregulation of TSG101 RNA is detected in PTC specimens by in situ hybridization and semi-quantitative RT -PCR The overexpression of TSG101 transcripts in PTC cells of these samples was further demonstrated by in situ hybridization with TSG101 antisense riboprobe (Figures 2e and 3e) . The specificity of hybridization ensured that the control experiment using sense riboprobe gave no signal on the section of the same specimen (Figure 3f ). The results of immunohistochemical staining and in situ hybridization are summarized in Table 1 . Most of the cases gave consistent and unambiguous results using both assays, whereas the in situ hybridization signals were weak in specimens 4 and 7 and focal in specimen 16. Two of the samples, no. 2 and 9, showed no signal. The arbitrary hybridization patterns were probably caused by poor RNA quality in these samples since there was no signal in their adjacent normal follicular cells. To further verify the relative amount of TSG101 transcripts in tumor and normal thyroid tissues, semi-quantitative RT -PCR and subsequent Southern hybridizations were performed. Limited by the availability of fresh tissue samples, only three normal thyroid tissues and three PTCs samples were analysed. The PCR conditions verified that the reactions were in a linear range and not in a plateau, and were, therefore, suitable for comparing mRNA amounts. To compare the amounts of the amplified TSG101 products, we performed a quantification of the hybridization signals ( Figure 4a ) with a densitometric scanner (GS-700 Imaging Densitometer, BIO-RAD Laboratories, Hercules, CA, USA).
The value obtained by densitometry scanning of TSG101 hybridization signal was normalized to the value obtained from the signal of GAPDH internal control in the corresponding sample. As indicated in Figure 4b , the relative amount of TSG101 expression in the tumor sample was more than twofold higher than that found in normal samples.
Discussion
In this report, we demonstrate overexpression of TSG101 gene in human PTCs by both immunohisto- chemistry and in situ hybridization. The role of TSG101 as an inactive homologue of ubiquitinconjugated enzymes (Koonin and Abagyan, 1997; Ponting et al., 1997) has recently been demonstrated in regulating the steady-state level of MDM2 degradation, and this might account for the mechanism operated by TSG101 in the cell cycle control. Upregulation of MDM2 in cells that overexpress TSG101 conversely decreases the amount of p53 . Hence, overexpression of TSG101 might play an oncogenic role by inactivating p53 through MDM2 upregulation. Our findings provide the first evidence for the association of TSG101 overexpression with human PTCs. Since other reports have shown that MDM2 protein is upregulated in a high proportion of PTC specimens (Jennings et al., 1995;  Knauf et al Abstract of Post No. P2-528. The Endocrine Society's 83rd annual meeting, 2001), the same mechanism might likely be responsible for the TSG101 overexpression in mediating human PTC.
The steadiness box region of TSG101 was shown to control the steady-state level of TSG101. Mutation in this region caused the accumulation of TSG101 protein within the cells. However, no mutation in the steadiness box region in our sequence analysis of 17 PTC specimens overrules this possibility. We have performed nested RT -PCR on these PTC specimens following the protocol of Li et al. (1997) . The truncated forms of TSG101 transcripts were detected in a small number of samples (two out of 20 samples, data not shown). Hence, it is unlikely that the aberrant protein translated from the truncated TSG101 RNA might account for the upregulated-TSG101 protein detected by immunohistochemical staining. However, it remains possible that mutation in another part of TSG101, which we have not sequenced might account for the accumulation of TSG101 in PTC cells. The results of our in situ hybridization analysis confirm that TSG101 was up-regulated in the RNA level, indicating that there might be differential RNA stability or promoter activity in normal thyroid cells and PTC cells. Further experiments are needed to clarify this issue.
In this study, while TSG101 expression was primarily localized in the cytoplasm of PTC tumor cell, either negative or only dot-staining was observed in the cytoplasm of non-neoplastic follicular cells. Occasionally, the staining could be seen in the nucleus. The ability of the TSG101 protein to shuttle between different locations during the cell cycle is consistent with the notion that this gene product may function in both nucleus and cytoplasm (Xie et al., 1998; Zhong et al., 1998) . The diffused cytoplasmic localization of TSG101 protein was prominent in PTC cells in TSG101 cDNA nucleotides 803 -1263 encompassing steadiness box was amplified by PCR using TSG-803 and TSG-R primers, and the sequence status was determined by automatic sequencing. 7: no mutation, ND: not determined (Figures 2c and 3d) , reminiscent of the dispersed TSG101 staining pattern in cell treated with brefeldin A that interferes with the protein transportation in the membrane compartments (Xie et al., 1998) . It remains to be determined whether the diffused TSG101 localization pattern we observed is merely the reflection of the cell cycle status of carcinoma cells or due to a defect in the process of subcellular localization in neoplastic cells.
TSG101 has been shown to repress ligand-dependent transcriptional activation by receptors such as androgen receptor, estrogen receptor, glucocorticoid receptor, vitamin D receptor, retinoid acid receptor and thyroid hormone receptor (Sun et al., 1999; Watanabe et al., 1998) . In the case of glucocorticoid receptor, the repression was mediated through the direct binding of TSG101 to the GR AF-1 transcriptional activation domain of glucocorticoid receptor (Hittelman et al., 1999) . Recent reports imply that TSG101 is essential for normal membrane trafficking and regulation of receptor recycling (Babst et al., 2000; Bishop and Woodman, 2000) . Forced expression of TSG101 could suppress receptor function indirectly by interfering with the regulation of membrane trafficking and receptor recycling. Therefore, it is tempting to speculate whether aberrant receptor recycling control due to overexpression of TSG101 might resolve in abnormal cell growth in PTC cells. On the other hand, it has been shown that TSG101 could suppress transcription by direct association with DMAP1 and DNMT1 containing transcription repression complex (Rountree et al., 2000) . It is possible that the deranged steady-state of TSG101 protein level interferes with the regulation normally operated to control the growth of thyroid cells through nuclear receptors. In addition, the coiled-coil domain at carboxyl terminus of TSG101 protein has been reported to interact with the cytoplasmic phosphoprotein, stathmin/oncoprotein 18 (Maucuer et al., 1995) , the latter possibly playing a role in microtubule dynamics as well as cell growth and differentiation. A further examination of the relation between TSG101 overexpression and stathmin/oncoprotein 18 in mediating the formation of PTC would be interesting.
Materials and methods
Plasmid construction
The IMAGE Consortium cDNA clones, No. 547885 and 684503, containing cDNAs (nucleotides 88 -964 and 734 -1492, respectively) of human TSG101 were purchased from Research Genetics, Inc., (Huntsville, AL, USA). The cDNA inserts were cloned individually into appropriate pGEX4T vectors (Pharmacia, Uppsala, Sweden) for the expression of TSG101 protein fused in frame with glutathione S-transferase (GST). Recombinant plasmids were then sequenced using GST gene specific primer to confirm the in-frame recombinant sequences.
Fusion protein and antiserum production
Transformed DH5a bacteria containing recombinant plasmid were grown in LB broth containing 200 mg/ml ampicillin at 378C until the OD 600 reached 0.5. Fusion protein expression was then induced after the addition of isopropyl-1-thio-b-Dgalactopyranoside (final concentration of 0.5 mM). Fusion protein was then purified into homogeneity by affinity chromatography on glutathione-conjugated agarose beads (Sigma, St. Louis, MO, USA) as previously described (Hsu et al., 1998) . Purified fusion protein was concentrated by using a Centricon TM 30 concentrator (Amicon Inc., Beverly, MA, USA) and resuspended in 200 mM phosphate buffer, pH 7.0. Antiserum was prepared as described in a previous publication (Hsu et al., 1998) . For preparation of GSTabsorbed antiserum, immunized rabbit serum (antiserum #654) was preabsorbed three times with GST protein bound nitrocellulose membranes.
Cell culture
Human hepatoma cell line SK-Hep-1 was routinely maintained in Dulbecco's modified Eagle Medium supplemented with 10% fetal calf serum (Hyclone 1 Laboratories, Inc., Logan, UT, USA), and cultured at 378C in a 5% CO 2 incubator.
Western blot analysis
Whole cell lysate and prestained protein molecular weight markers were electrophoresed on 12.5% SDS -PAGE gel and transferred onto nitrocellulose membrane using a semidried blotting apparatus (Biometra, Go¨ttingen, Germany). The membrane was blocked with blocking buffer (5% skim milk in TBS-T; 0.8% NaCl; 0.02% KCl; 25 mM Tris-HCl, pH 7.4; 0.05% Tween 20) for 1 h. Primary antibody (1 : 2000 dilution in blocking buffer containing 1% NP-40) was added and incubated at 48C overnight. The membrane was again washed four times with TBS-T and subsequently incubated with horseradish peroxidase-conjugated secondary antibody (1 : 4000 dilution in blocking buffer containing 1% NP-40). The membrane was then further washed four times with TBS-T. The immunoblot was then developed with SuperSignal TM CL-HRP chemiluminescent substrate according to the protocol recommended by the manufacturer (Pierce, Rockford, IL, USA).
Tissue samples
Twenty clinical specimens of PTCs were collected from the patients during surgery for thyroidectomy, and fixed in 10% buffered formalin and embedded in paraffin. Normal human thyroid tissues were obtained with informed consent from patients who had undergone surgical removal of parathyroid adenoma. Tumor tissues used for RT -PCR analysis were snap frozen in liquid nitrogen when the diagnosis of PTC was confirmed.
Immunohistochemistry
The paraffin-embedded tissue blocks were sectioned in 5 mm slices and placed on slides coated with poly-L-lysine. The sections were then dewaxed and incubated in a 378C oven. After overnight incubation, the slides were rinsed in phosphate buffered saline (PBS) and blocked for 5 min with 3% hydrogen peroxide to deprive the endogenous peroxidase activity. After antigen retrieval, primary antibodies (1 : 100 dilution in PBS) were applied onto the specimens and incubated for 30 min. The sections were then washed with PBS. Biotinylated secondary antibody and streptavidinhorseradish peroxidase were applied to the specimens in succession according to the manufacturer's instructions (LSAB 1 Plus Kit, DAKO, Denmark). After extensive washing, peroxidase substrate diaminobenzidine (Sigma) was added, and the specimens were incubated for 5 min. Thereafter, the sections were counter-stained with Mayer's hematoxylin for 2 min, washed in running water for 5 min, dehydrated with serial ethyl alcohol and cleared with xylene. Finally, the slides were mounted with mounting medium. The results were observed under the microscope.
In situ hybridization
The plasmid pBluescript SK(7) that contained TSG101 cDNA encoding amino acid residues 1 -291 was used for the preparation of riboprobes. To generate anti-sense probe, plasmid DNA was linearized by EcoRI digestion and transcribed by T7 RNA polymerase. For the negative control sense probe, plasmid DNA was linearized with KpnI digestion and then transcribed with T3 RNA polymerase using a DIG RNA labeling kit (Roche, Mannheim, Germany) according to the manufacturer's instructions. To perform in situ hybridization study, 4 mm consecutive sections of paraffinembedded sample were processed as for immunohistochemistry. Rehydrated sections were then rinsed twice in diethylpyrocarbonate (DEPC)-treated water followed by DEPC-treated PBS, and digested with 20 mg/ml proteinase K (DAKO) at 378C for 45 min. Proteinase K was then removed by washing them two times in DEPC-treated PBS. To acetylate the sections, the slides were immersed in 0.1 M triethanolamine buffer, pH 8.0, containing 0.25% acetic anhydride for 10 min at room temperature and then rinsed with 56 sodium chloride/sodium citrate (SSC) solution for 5 min. The sections were then prehybridized with 50% deionized formamide in 56 SSC at 428C. After 1 h incubation, the prehybridization solution was removed and 30 ml heat-denatured riboprobe (3 ng/ml in mRNA in situ hybridization solution) was added on each section, which was then covered with coverslip and hybridized at 458C overnight in a humid chamber. After hybridization, the coverslips were removed by soaking in 26 SSC. The sections were then incubated with 20 mg/ml RNase A to digest non-hybridized probe. Stringent washing was performed by incubating the slides stepwise in 16, 0.26, 0.056 and 0.0256 SSC, consecutively. The endogenous peroxidase in the sections was quenched with 3% hydrogen peroxide at room temperature for 5 min. Thereafter, the slides were immersed in TBS-T followed by blocking with rabbit serum (DAKO). The sections were then incubated with 1 : 100 diluted rabbit HRP-anti-DIG antibody (DAKO) for 1 h at room temperature. The DAKO GenPoint kit for catalyzed reporter deposition was then used to amplify the signal. Briefly, the slides were washed with TBS-T, incubated with biotinyltyramide solution for 15 min, washed with TBS-T, and incubated with streptavidin-HRP for 15 min followed by TBS-T wash. Finally, the slides were incubated with DAB for 5 min to develop the signal. Gill's hematoxylin (Merck, Darmstadt, Germany) was used for counterstaining before mounting.
RT -PCR and Southern blotting
Total RNA was extracted from clinical specimens using Trizol 1 reagent (Life Technologies, Gaithersburg, MD, USA) according to manufacturer's instructions. First-strand cDNA was synthesized from 100 nanogram of total RNA using the Advantage TM RT-for-PCR kit (Clontech Laboratories, Palo Alto, CA, USA) in a 25 ml of reaction volume. The reverse transcription product was diluted with DEPCtreated water into a final volume of 100 ml. Then, 3 ml of the first strand cDNA was mixed with 5 ml of 106 PCR buffer, 4 ml of 2.5 mM dNTP, 1.4 ml of 10 mM TSG101 specific forward primer (TSG-F, 5'-AGCTCAAGAAAATGGTGTC-CAAGTAC-3'), 1.4 ml of 10 mM TSG101 reverse primer (TSG-R, 5'-CAGCTGGTATCAGAGAAGTCAGTAG-3') and 1 ml of Taq polymerase (TaKaRa Biomedicals, Shiga, Japan). The mixture was incubated at 958C for 5 min. Then, the PCR reaction was performed with denaturation at 968C for 45 s; annealing at 658C for 1 min; and extension at 728C for 1 min. The complete amplification procedure was carried out for 35 cycles followed by further incubation at 728C for 10 min. In order to control for errors in input of cDNA used in PCR reaction, amplification of the ubiquitous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was performed in parallel using GAPDH specific primers (forward: 5'-ACCACAGTCCATGCCATCAC-3'; reverse: 5'-TCCACCACCCTGTTGCTGTA-3').
Aliquots of PCR product were size-fractionated by agarose gel electrophoresis, transferred onto Hybond-N membrane (Amersham, Chicago, IL, USA) and prehybridized for 1 h at 428C in ExpressHyb TM hybridization solution (Clontech) and then hybridized with 1610 7 c.p.m. of 32 P-end-labeled internal probes for overnight at 378C. The membrane was then washed twice with 26 SSC, 0.5% SDS at 378C for 10 min. Membrane was then autoradiographed on Kodak film XAR at 7708C. The nucleotide sequences of the probes were TSG-803, 5'-TGAGATGGCGGATGAAGG-3' for TSG101, 5'-GCCACC-CAGAAGACTGTGGATGGCCCCTCC-3' for GAPDH. Abbreviations TSG101, tumor susceptibility gene 101; PTC, papillary thyroid carcinoma; IHC, immunohistochemistry; ISH, in situ hybridization; GST, glutathione S-transferase
